+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
At-home Drug of Abuse Testing Market - Global Forecast 2026-2032- Product Image
At-home Drug of Abuse Testing Market - Global Forecast 2026-2032- Product Image
Sale

At-home Drug of Abuse Testing Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • July 2026
  • Region: Global
  • 360iResearch™
  • ID: 5716235
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The At-home Drug of Abuse Testing Market is projected to reach USD 863.18 Million in 2026. It is expected to continue growing at a CAGR of 5.53%, reaching USD 1.19 Billion by 2032.

At-home drug of abuse testing is moving from a niche self-screening tool to a broader health, workplace, family safety, and recovery-support solution. These tests typically use urine, saliva, hair, or breath samples to detect substances such as cannabis, opioids, cocaine, amphetamines, benzodiazepines, and alcohol metabolites, with formats ranging from rapid immunoassay strips and cups to mail-in laboratory confirmation models. Demand is being shaped by the persistence of substance use disorders, the expansion of telehealth-enabled care, growing awareness of fentanyl and polysubstance risks, and the need for discreet, accessible testing outside clinical settings. The category sits at the intersection of diagnostics, digital health, toxicology, privacy regulation, and public health policy. Executive attention is increasingly focused on test accuracy, chain-of-custody integrity, user comprehension, confirmatory testing access, data protection, and compliance with regional regulations governing medical devices, workplace testing, and consumer diagnostics.

Transformative Shifts in the At-home Testing Landscape

The at-home drug of abuse testing landscape is being reshaped by five structural shifts. First, the opioid crisis and rising concern around fentanyl exposure have increased interest in frequent, low-barrier screening, especially when paired with counseling, medication-assisted treatment, or harm-reduction services. Second, oral fluid testing is gaining relevance because of its noninvasive collection, observed-sample potential, and closer alignment with recent drug use compared with some urine-based formats. Third, e-commerce and pharmacy distribution are improving access while intensifying scrutiny around labeling, result interpretation, and post-test guidance. Fourth, telehealth integration is turning testing into a connected service, enabling remote verification, clinical consultation, recovery monitoring, and referral pathways. Fifth, evolving cannabis legalization, workplace safety obligations, and criminal justice reforms are changing how results are interpreted, particularly because detection does not always equal impairment. These shifts are making reliability, ethical use, and consumer education as important as detection capability.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence at-home drug testing through digital interpretation, workflow automation, risk stratification, and user support. Smartphone-assisted reading can help standardize visual interpretation of lateral flow test lines, reducing ambiguity caused by faint bands, lighting conditions, or user error. AI-enabled applications can also guide sample collection, flag invalid tests, document timing, and support secure transmission of results to authorized clinicians or program administrators. In care settings, algorithmic tools may help identify relapse risk patterns when testing data are combined with consented behavioral, treatment adherence, and telehealth information. However, AI introduces critical governance requirements. Drug testing results carry legal, employment, medical, and social consequences, so AI systems must be transparent, validated, bias-monitored, privacy-preserving, and aligned with medical device and data protection regulations. The strongest use cases are those that improve quality control, accessibility, and linkage to care rather than replacing laboratory confirmation or professional judgment.

Key Regional Insights

In Asia-Pacific, demand for at-home drug of abuse testing is influenced by large population bases, expanding digital health adoption, e-commerce access, and diverse regulatory approaches to controlled substances, with China, India, Japan, South Korea, Australia, and ASEAN economies showing different levels of consumer diagnostic acceptance, privacy governance, and enforcement intensity. North America remains a highly active environment due to opioid and fentanyl-related harms, widespread workplace and recovery testing, established retail and mail-in laboratory channels, and strong attention to confirmatory toxicology workflows and privacy obligations. Latin America is shaped by urbanization, cross-border drug trafficking concerns, occupational safety needs, and uneven access to laboratory infrastructure, which can make affordable point-of-care and at-home formats relevant when paired with clinical oversight and clear referral pathways. Europe emphasizes regulatory compliance, privacy, and medical device quality under harmonized frameworks, while national differences in workplace testing, cannabis policy, and labor protections influence adoption. In the Middle East, strict drug laws, aviation and transportation safety requirements, expatriate workforce screening, and expanding private healthcare systems support interest in reliable screening, although cultural sensitivity and legal consequences require careful deployment. In Africa, growing public health needs, youth substance use concerns, and limited centralized testing access create potential for decentralized screening, but affordability, supply chain robustness, user education, and confirmatory testing availability remain decisive factors.

Key Group Insights

Across ASEAN, rising healthcare digitization, young demographics, expanding pharmacy access, and workplace safety needs are creating opportunities for accessible drug screening, although regulatory maturity, laboratory capacity, and enforcement practices vary substantially among member states. GCC countries combine strict anti-drug policies, large expatriate workforces, aviation and industrial safety priorities, and strong investment in healthcare infrastructure, making compliant, well-documented testing systems particularly relevant in occupational and clinical contexts. The European Union places strong emphasis on privacy, medical device conformity, consumer safety, and evidence-based labeling, which supports high-quality at-home drug testing solutions but raises the compliance threshold for products that generate health-related data. BRICS economies reflect diverse drivers: Brazil faces public health and security pressures, Russia maintains stringent controlled-substance enforcement, India and China bring large-scale access, digital commerce, and manufacturing considerations, and South Africa highlights the importance of affordability and community-level health services. G7 markets generally demonstrate mature healthcare systems, broader pharmacy and e-commerce access, strong toxicology infrastructure, and higher expectations for accuracy, data security, and integration with treatment pathways. NATO member countries add defense, transportation, and critical infrastructure safety considerations, where testing reliability, chain-of-custody procedures, auditable documentation, and standardized result handling are especially important.

Key Country Insights

In the United States, at-home drug testing is shaped by opioid and fentanyl-related harms, recovery monitoring, workplace policies, telehealth use, and a complex regulatory environment for diagnostics, privacy, and employment testing. Canada’s adoption is influenced by cannabis legalization, harm-reduction policy, public healthcare integration, and privacy expectations. Mexico reflects occupational safety needs, cross-border drug concerns, and uneven access to confirmatory laboratory services. Brazil combines large urban populations, public security challenges, and healthcare access gaps that support interest in decentralized screening. The United Kingdom emphasizes clinical governance, pharmacy access, and workplace policy clarity, while Germany, France, Italy, and Spain each balance medical device compliance, data protection rules, cannabis or controlled-substance policy shifts, and national labor protections. Russia’s strict drug control environment affects testing use and interpretation, particularly where legal consequences are significant. China’s scale, digital commerce infrastructure, domestic diagnostics capacity, and regulatory oversight create a distinctive pathway for consumer diagnostics, while India’s large population, expanding diagnostics sector, rising telemedicine adoption, and affordability needs support demand for easy-to-use formats. Japan prioritizes quality, reliability, and regulatory discipline; Australia combines workplace safety, remote access needs, road safety priorities, and established public health awareness; and South Korea’s advanced digital health environment and strict controlled-substance policies support interest in accurate, well-governed testing solutions.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically credible, user-centered, and regulation-ready at-home drug testing solutions. Product development should emphasize validated accuracy, clear instructions, built-in quality controls, tamper-evident collection where appropriate, and access to confirmatory laboratory testing for non-negative results. Digital features should be designed around consent, privacy, auditability, cybersecurity, and interoperability with telehealth or care management systems. Educational content must clearly explain detection windows, limitations, false positives, false negatives, specimen validity, and the difference between drug exposure and impairment. Organizations serving workplace, recovery, criminal justice, or family-use scenarios should establish ethical testing protocols, documented consent practices, and pathways to counseling, harm-reduction resources, or medical care. Regional commercialization strategies should account for medical device requirements, consumer diagnostic rules, employment law, data protection statutes, telehealth policies, and cultural expectations. Leaders that combine reliable testing, responsible data handling, and post-result support will be better positioned than those competing solely on convenience or price.

Research Methodology

A robust assessment of at-home drug of abuse testing requires triangulation of verified public health, regulatory, clinical, and industry evidence. The research approach should review guidance from health authorities, toxicology and laboratory medicine standards, medical device regulations, workplace testing frameworks, peer-reviewed studies on drug detection methods, and publicly available information on substance use trends. Primary inputs should include perspectives from toxicologists, laboratory directors, clinicians, addiction medicine specialists, pharmacists, occupational health professionals, digital health experts, and regulatory advisors. Product evaluation should compare sample types, detection windows, analytical sensitivity and specificity, cutoff levels, user error risks, specimen validity checks, confirmatory testing pathways, packaging claims, and digital data practices. Regional and country analysis should examine legal status of substances, privacy laws, labor regulations, healthcare access, telehealth maturity, retail and e-commerce distribution, and laboratory confirmation capacity. Findings should be validated through cross-source consistency checks, expert review, and exclusion of unsupported claims, especially where drug testing outcomes may affect employment, legal standing, or clinical decisions.

Conclusion

At-home drug of abuse testing is becoming an important part of decentralized diagnostics, substance use monitoring, workplace safety, and digitally enabled care. Its value depends not only on rapid detection but also on accuracy, responsible interpretation, privacy protection, and linkage to professional support. The strongest opportunities are emerging where at-home testing complements, rather than replaces, laboratory confirmation and clinical judgment. As AI, telehealth, and e-commerce expand the category, stakeholders must address ethical, regulatory, and user-experience challenges with discipline. Products and programs that deliver validated performance, transparent guidance, secure data handling, and culturally appropriate implementation will be best aligned with public health needs and long-term trust in at-home drug testing.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. At-home Drug of Abuse Testing Market, by Product Type
7.1. Introduction
7.2. Drug Test Kits
7.2.1. Single-panel drug test kits
7.2.2. Multi-panel drug test kits
7.3. Drug Test Strips
7.4. Drug Test Cassettes
7.5. Drug Test Cups
8. At-home Drug of Abuse Testing Market, by Sample Type
8.1. Introduction
8.2. Hair
8.3. Saliva
8.4. Blood
8.5. Urine
9. At-home Drug of Abuse Testing Market, by Drug Type
9.1. Introduction
9.2. Marijuana
9.3. Cocaine
9.4. Opioids
9.5. Amphetamines
10. At-home Drug of Abuse Testing Market, by Technology
10.1. Introduction
10.2. Chromatography
10.2.1. Gas Chromatography-Mass Spectrometry
10.2.2. Liquid Chromatography-Mass Spectrometry
10.3. Immunoassay-Based Testing
10.4. Lateral Flow Assay-Based
11. At-home Drug of Abuse Testing Market, by End User
11.1. Introduction
11.2. Individuals
11.3. Rehabilitation & Recovery Patients
11.4. Law Enforcement & Legal Monitoring Firms
11.5. Sports & Athletics Firms
12. At-home Drug of Abuse Testing Market, by Distribution Channel
12.1. Introduction
12.2. Online Retail
12.3. Offine Retail
13. At-home Drug of Abuse Testing Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. At-home Drug of Abuse Testing Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. At-home Drug of Abuse Testing Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. ACON Laboratories Inc.
17.3. AdvaCare Pharma
17.4. AllTest Biotech Co., Ltd.
17.5. American Screening Corporation
17.6. Bio-Rad Laboratories Inc.
17.7. BTNX Inc.
17.8. Confirm Biosciences Inc.
17.9. Creative Diagnostics
17.10. First Check Diagnostics Corp.
17.11. Germaine Laboratories, Inc.
17.12. InTec PRODUCTS, INC.
17.13. Laboratory Corporation of America Holdings
17.14. Medtox Laboratories Inc.
17.15. OraSure Technologies Inc.
17.16. Phamatech, Inc.
17.17. Premier Biotech, Inc.
17.18. Quest Diagnostics Incorporated
17.19. Safecare Biotech (Hangzhou) Co., Ltd.
17.20. Screen Italia S.r.l.
17.21. Siemens Healthineers AG
17.22. Sure Screen Diagnostics Ltd.
17.23. Thermo Fisher Scientific Inc.
17.24. Wondfo Biotech Co., Ltd.
List of Figures
FIGURE 1. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DRUG TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DRUG TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DRUG TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL SINGLE-PANEL DRUG TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL SINGLE-PANEL DRUG TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL SINGLE-PANEL DRUG TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MULTI-PANEL DRUG TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MULTI-PANEL DRUG TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MULTI-PANEL DRUG TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DRUG TEST STRIPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DRUG TEST STRIPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DRUG TEST STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DRUG TEST CASSETTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DRUG TEST CASSETTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DRUG TEST CASSETTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DRUG TEST CUPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DRUG TEST CUPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DRUG TEST CUPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL HAIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL HAIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL HAIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MARIJUANA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MARIJUANA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MARIJUANA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL COCAINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL COCAINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL COCAINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL AMPHETAMINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL AMPHETAMINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL AMPHETAMINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL IMMUNOASSAY-BASED TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL IMMUNOASSAY-BASED TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL IMMUNOASSAY-BASED TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL LATERAL FLOW ASSAY-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL LATERAL FLOW ASSAY-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL LATERAL FLOW ASSAY-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL INDIVIDUALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL INDIVIDUALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL INDIVIDUALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL REHABILITATION & RECOVERY PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL REHABILITATION & RECOVERY PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL REHABILITATION & RECOVERY PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL LAW ENFORCEMENT & LEGAL MONITORING FIRMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL LAW ENFORCEMENT & LEGAL MONITORING FIRMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL LAW ENFORCEMENT & LEGAL MONITORING FIRMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL SPORTS & ATHLETICS FIRMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL SPORTS & ATHLETICS FIRMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL SPORTS & ATHLETICS FIRMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ONLINE RETAIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ONLINE RETAIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ONLINE RETAIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL OFFINE RETAIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL OFFINE RETAIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL OFFINE RETAIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 94. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 96. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 97. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 98. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 99. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 100. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 101. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 123. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 124. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 125. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 126. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 127. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 128. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. NATO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. NATO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 142. NATO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 143. NATO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 144. NATO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 145. NATO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 146. NATO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 147. NATO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. NATO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. G7 AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. G7 AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 151. G7 AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 152. G7 AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 153. G7 AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 154. G7 AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 155. G7 AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 156. G7 AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. G7 AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. BRICS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 159. BRICS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 160. BRICS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 161. BRICS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 162. BRICS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 163. BRICS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 164. BRICS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 165. BRICS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. BRICS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 177. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 178. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 179. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 180. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 181. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 182. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 183. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 184. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 185. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 186. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 187. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 188. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 189. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 190. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 191. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 192. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. CHINA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 196. CHINA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 197. CHINA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 198. CHINA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 199. CHINA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 200. CHINA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 201. CHINA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 202. CHINA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. CHINA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 213. JAPAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 214. JAPAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 215. JAPAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 216. JAPAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 217. JAPAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 218. JAPAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 219. JAPAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 220. JAPAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. JAPAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. INDIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 223. INDIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 224. INDIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 225. INDIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 226. INDIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 227. INDIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 228. INDIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 229. INDIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. INDIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. GERMANY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 232. GERMANY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 233. GERMANY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 234. GERMANY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 235. GERMANY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 236. GERMANY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 237. GERMANY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 238. GERMANY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 239. GERMANY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. UNITED KINGDOM AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 241. UNITED KINGDOM AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 242. UNITED KINGDOM AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 243. UNITED KINGDOM AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 249. AUSTRALIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 250. AUSTRALIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 251. AUSTRALIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 252. AUSTRALIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 253. AUSTRALIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 254. AUSTRALIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 255. AUSTRALIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 256. AUSTRALIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 257. AUSTRALIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 258. FRANCE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 259. FRANCE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 260. FRANCE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 261. FRANCE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 262. FRANCE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 263. FRANCE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 264. FRANCE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 265. FRANCE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 266. FRANCE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 267. SOUTH KOREA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 268. SOUTH KOREA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 269. SOUTH KOREA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 270. SOUTH KOREA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 271. SOUTH KOREA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 272. SOUTH KOREA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 273. SOUTH KOREA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 274. SOUTH KOREA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 275. SOUTH KOREA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 276. ITALY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 277. ITALY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 278. ITALY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 279. ITALY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 280. ITALY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 281. ITALY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 282. ITALY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 283. ITALY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 284. ITALY AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 285. CANADA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 286. CANADA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 287. CANADA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 288. CANADA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 289. CANADA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 290. CANADA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 291. CANADA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 292. CANADA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 293. CANADA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 294. RUSSIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 295. RUSSIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 296. RUSSIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 297. RUSSIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 298. RUSSIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 299. RUSSIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 300. RUSSIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 301. RUSSIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 302. RUSSIA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 303. BRAZIL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 304. BRAZIL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 305. BRAZIL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 306. BRAZIL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 307. BRAZIL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 308. BRAZIL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 309. BRAZIL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 310. BRAZIL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 311. BRAZIL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 312. MEXICO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 313. MEXICO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 314. MEXICO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 315. MEXICO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 316. MEXICO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 317. MEXICO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 318. MEXICO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 319. MEXICO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 320. MEXICO AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 321. SPAIN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 322. SPAIN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 323. SPAIN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TEST KITS, 2018-2032 (USD MILLION)
TABLE 324. SPAIN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 325. SPAIN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 326. SPAIN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 327. SPAIN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
TABLE 328. SPAIN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 329. SPAIN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 330. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SHARE, BY KEY PLAYER, 2025
TABLE 331. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • ACON Laboratories Inc.
  • AdvaCare Pharma
  • AllTest Biotech Co., Ltd.
  • American Screening Corporation
  • Bio-Rad Laboratories Inc.
  • BTNX Inc.
  • Confirm Biosciences Inc.
  • Creative Diagnostics
  • First Check Diagnostics Corp.
  • Germaine Laboratories, Inc.
  • InTec PRODUCTS, INC.
  • Laboratory Corporation of America Holdings
  • Medtox Laboratories Inc.
  • OraSure Technologies Inc.
  • Phamatech, Inc.
  • Premier Biotech, Inc.
  • Quest Diagnostics Incorporated
  • Safecare Biotech (Hangzhou) Co., Ltd.
  • Screen Italia S.r.l.
  • Siemens Healthineers AG
  • Sure Screen Diagnostics Ltd.
  • Thermo Fisher Scientific Inc.
  • Wondfo Biotech Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages198
PublishedJuly 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 863.18 Million
Forecasted Market Value ( USD ) by 2032 $ 1190 Million
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Drug of Abuse Testing Market by Sample Type, Test Technology, Drug Panel, End User - Global Forecast 2026-2032 - Product Image

Drug of Abuse Testing Market by Sample Type, Test Technology, Drug Panel, End User - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
At-Home Drug of Abuse Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

At-Home Drug of Abuse Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Drug of Abuse Testing Market Report 2026 - Product Image

Drug of Abuse Testing Market Report 2026

  • Report
  • 250 Pages
  • Global
From
At-Home Drug of Abuse Testing Market Outlook 2026-2034: Market Share and Growth Analysis by Type (Test Cups, Test Strips, Others), Sample Type - Product Image

At-Home Drug of Abuse Testing Market Outlook 2026-2034: Market Share and Growth Analysis by Type (Test Cups, Test Strips, Others), Sample Type

  • Report
  • 160 Pages
  • Global
From
Drugs of Abuse Testing Market Insights, Competitive Landscape, and Market Forecast - 2033 - Product Image

Drugs of Abuse Testing Market Insights, Competitive Landscape, and Market Forecast - 2033

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.